Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 2015

View Archived Issues

Researchers identify biomarkers for colorectal cancer blood test

Sangamo Biosciences to target BCL11A for beta-thalassemia and SCD

Lilly initiates phase III trial of anti-CGRP MAb in cluster headache

Phase I results for CV-9104

ValiRx updates on progress of ValiSeek's VAL-401

Phase I trial initiated for Emergent and GSK Ebola virus vaccine prime-boost regimen

DI-B4 monoclonal antibody well-tolerated in NHL and CLL patients

Initiation of a phase I/Ib trial of TG-1050

Agilis licenses Angelman syndrome gene therapy from University of South Florida

Sanofi licenses immunotherapeutic for celiac disease from Selecta Biosciences

Ono Pharmaceutical updates pipeline progress of fourth quarter of fiscal 2014

GlycoOptimization technology shows promising results for cancer therapy

Antabio receives funding to develop drugs for P. aeruginosa infection in CF patients

HA bioconjugates: intracellular drug delivery sistem with enhanced safety

FORUM develops Abeta production inhibitors

Novartis patents ERK2 inhibitors

Idenix disclose anti-HCV nucleotide prodrugs

BioCryst starts phase I trial of second-generation oral kallikrein inhibitor for HAE

Bayer presents compounds for bleeding disorders

TB Alliance initiates phase III trial of triple oral drug regimen in XDR-TB

Phase I trial initiated for Jiangsu Jindike Biotechnology influenza vaccine

PharmaMar's lurbinectedin enters phase III trial in ovarian, fallopian tube and peritoneal cancer

SYM-1219 enters phase III trial for bacterial vaginosis

AAV-Nrf2 rescues retinal function in AMD mouse model

Emergent BioSolutions to conduct process development for Soligenix's RiVax

Denali Therapeutics launched to develop neurodegenerative disease therapeutics

GlycoMimetics' GMI-1271 receives FDA orphan drug designation for AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...